What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms

被引:2
作者
Freeman, Jeffrey S. [1 ]
Horton, Edward S. [2 ]
机构
[1] Philadelphia Coll Osteopath Med, Div Endocrinol & Metab, Philadelphia, PA 19131 USA
[2] Joslin Diabet Ctr, Boston, MA 02215 USA
关键词
type; 2; diabetes; management; efficacy; safety; ADD-ON THERAPY; INADEQUATE GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; PROTAMINE HAGEDORN INSULIN; INCRETIN-BASED THERAPIES; TWICE-DAILY EXENATIDE; TO-TARGET TRIAL; BASAL INSULIN; DOUBLE-BLIND;
D O I
10.1097/MJT.0b013e31826fc5e5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.
引用
收藏
页码:449 / 464
页数:16
相关论文
共 50 条
  • [21] Insulin initiation in type 2 diabetes: What are the treatment regimen options and how can we best help patients feel empowered?
    Spollett, Geralyn R.
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2012, 24 : 249 - 259
  • [22] COVID-19 and diabetes: What have we learned so far?
    Taher, Nida
    Huda, Mohammed S. B.
    Chowdhury, Tahseen A.
    CLINICAL MEDICINE, 2020, 20 (04) : E87 - E90
  • [23] What have we learned from cancer immunotherapy in the last 3 years?
    Ascierto, Paolo A.
    Marincola, Francesco M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [24] SGLT2 inhibitors in the treatment of type 2 diabetes
    Hasan, Farhad M.
    Alsahli, Mazen
    Gerich, John E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
  • [25] Prevention of type 1 diabetes:: what have we achieved?: What should we say and propose next to families?
    Vialettes, B
    Valéro, R
    Mattei, C
    Nervi, S
    DIABETES & METABOLISM, 2003, 29 (06) : 650 - 654
  • [26] Therapeutic medications against diabetes: What we have and what we expect
    Hu, Cheng
    Jia, Weiping
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 139 : 3 - 15
  • [27] Food Allergy and Quality of Life: What Have We Learned?
    van der Velde, Jantina L.
    Dubois, Anthony E. J.
    Flokstra-de Blok, Bertine M. J.
    CURRENT ALLERGY AND ASTHMA REPORTS, 2013, 13 (06) : 651 - 661
  • [28] Treatment of Type 2 Diabetes with Sitagliptin - A Noninterventional Study
    Kusterer, K.
    Ruessmann, H.-J.
    Voss, B.
    Bestehorn, K.
    DIABETOLOGIE UND STOFFWECHSEL, 2010, 5 (04) : 242 - 250
  • [29] Immunotherapy: The Meta-Analyses. What have we Learned?
    Calderon, Moises A.
    Boyle, Robert J.
    Penagos, Martin
    Sheikh, Aziz
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2011, 31 (02) : 159 - +
  • [30] Infantile hemangiomas: what have we learned from propranolol?
    Hagen, Rachael
    Ghareeb, Erica
    Jalali, Omid
    Zinn, Zachary
    CURRENT OPINION IN PEDIATRICS, 2018, 30 (04) : 499 - 504